This Article Full Text Full Text (PDF) All Versions of this Article: 46/1/19    most recent 01.HYP.0000169154.94803.35v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Redon, J. Search for Related Content PubMed PubMed Citation Articles by Redon, J. Related Collections Clinical Studies Related Article

(Hypertension. 2005;46:19.)
© 2005 American Heart Association, Inc.

Editorial Commentaries

Urinary Albumin Excretion

Lowering the Threshold of Risk in Hypertension

Josep Redon

From the Hypertension Clinic, Internal Medicine, Hospital Clínico, University of Valencia, Valencia, Spain.

Correspondence to Josep Redon, Hypertension Clinic, Internal Medicine, Hospìtal Clinico, Avda Blasco Ibañez, 17, 46010 Valencia, Spain. E-mail josep.redon@uv.es

An extract of the first 250 words of the full text is provided, because this article has no abstract.

During the past few years, a subtle increase in urinary albumin excretion (UAE) not detectable by routine methods, microalbuminuria, has become a prognostic marker for cardiovascular and/or renal risk in diabetic and nondiabetic subjects. Consequently, microalbuminuria assessment is now recommended in a risk stratification strategy not only in diabetic subjects but also for hypertension management. Microalbuminuria is defined as UAE from 30 to 300 mg/24 hours or equivalent amounts using timed overnight or spot urine samples (Table). The definition comes from studies that have established its value as a marker of risk for nephropathy in diabetic subjects. When the potential prognostic value of microalbuminuria on cardiovascular disease was being assessed in diabetic and nondiabetic populations, the threshold value pointing to an increment of risk was largely below the UAE value of 30 mg/24 hours regardless of the population studied.¹ Dammsgard² in an elderly population demonstrated that subjects with timed overnight UAE >7.5 µg/min had a higher mortality rate than those with lower values. Borch-Johnsen³ found, in a population-based cohort of 2085 consecutive subjects, the relative risk of ischemic heart disease associated with an spot urine albumin/creatinine ratio of only >0.65 mg/mmol was 2.3 when adjusted for other risk factors, Likewise, Jager, in the Hoorn study,⁴ a population-based cohort aged 50 to 75 years followed-up prospectively for 5 years, albumin/creatinine ratio >2.0 mg/mmol in a spot urine was associated with a 4-fold increase in cardiovascular mortality and 2-fold increase in all-cause mortality. Furthermore, in a cohort of postmenopausal women . . . [Full Text of this Article]

Related Article:

New Definition of Microalbuminuria in Hypertensive Subjects: Association With Incident Coronary Heart Disease and Death

Klaus Peder Klausen, Henrik Scharling, Gorm Jensen, and Jan Skov Jensen
Hypertension 2005 46: 33-37. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				G. F. Salles, R. Fiszman, C. R.L. Cardoso, and E. S. Muxfeldt Relation of Left Ventricular Hypertrophy With Systemic Inflammation and Endothelial Damage in Resistant Hypertension Hypertension, October 1, 2007; 50(4): 723 - 728. [Abstract] [Full Text] [PDF]

				J. Redon Measurement of microalbuminuria - what the nephrologist should know Nephrol. Dial. Transplant., March 1, 2006; 21(3): 573 - 576. [Full Text] [PDF]

				Defining Microalbuminuria in Hypertensive Patients Journal Watch Cardiology, August 12, 2005; 2005(812): 4 - 4. [Full Text]